ArticleMolecular & cellular proteomics : MCP2011
Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays.
Article in Molecular & cellular proteomics : MCP, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study.Blood cancer journal · 2016Trial
- Pan-disease blood protein profiles of rheumatic autoimmune diseases.Communications medicine · 2026Article
- V-Set Immunoglobulin Domain-Containing Protein 4 as a Novel Serum Biomarker of Lupus Nephritis and Renal Pathology Activity.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- Identification of a serum biomarker signature associated with metastatic prostate cancer.Proteomics. Clinical applications · 2021Article
- Proteomic Data Analysis for Differential Profiling of the Autoimmune Diseases SLE, RA, SS, and ANCA-Associated Vasculitis.Journal of proteome research · 2021Article
- Applications of Protein Microarrays in Biomarker Discovery for Autoimmune Diseases.Frontiers in immunology · 2021Review
- Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk.BMC cancer · 2020Article
- Curcumin Attenuates Both Acute and Chronic Immune Nephritis.International journal of molecular sciences · 2020Article
- Circulating Levels of Interferon Regulatory Factor-5 Associates With Subgroups of Systemic Lupus Erythematosus Patients.Frontiers in immunology · 2019Article
- Current applications of antibody microarrays.Clinical proteomics · 2018Review
- Article
- Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis.Molecular oncology · 2016Article
- Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study.Journal of proteome research · 2016Article
- Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics.PloS one · 2016Article
- Immunocapture strategies in translational proteomics.Expert review of proteomics · 2016Review
- Interfacing antibody-based microarrays and digital holography enables label-free detection for loss of cell volume.Future science OA · 2015Article
- Nanobodies and recombinant binders in cell biology.The Journal of cell biology · 2015Review
- A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma.International journal of proteomics · 2015Article
- Identification of plasma protein profiles associated with risk groups of prostate cancer patients.Proteomics. Clinical applications · 2014Article
- An integrated peptide-antigen microarray on plasmonic gold films for sensitive human antibody profiling.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are two severe autoimmune connective tissue diseases. The fundamental knowledge about their etiology is limited and the conditions display complex pathogenesis, multifaceted presentations, and unpredictable courses. Despite significant efforts, the lack of fully validated biomarkers enabling diagnosis, classification, and monitoring of disease activity represents significant unmet clinical needs. In this discovery study, we have for the first time used recombinant antibody microarrays for miniaturized, multiplexed serum protein profiling of SLE and SSc, targeting mainly immunoregulatory proteins. The data showed that several candidate SLE-associated multiplexed serum biomarker signatures were delineated, reflecting disease (diagnosis), disease severity (phenotypic subsets), and disease activity. Selected differentially expressed markers were validated using orthogonal assays and a second, independent patient cohort. Further, biomarker signatures differentiating SLE versus SSc were demonstrated, and the observed differences increased with severity of SLE. In contrast, the data showed that the serum profiles of SSc versus healthy controls were more similar. Hence, we have shown that affinity proteomics could be used to de-convolute crude, nonfractionated serum proteomes, extracting molecular portraits of SLE and SSc, further enhancing our fundamental understanding of these complex autoimmune conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.